Pure Biologics (WAR:PUR) EBIT: zł-6.58 Mil (TTM As of Mar. 2026)

What is Pure Biologics EBIT?

Pure Biologics WAR:PUR -3.69% 20 EBIT is zł-6.58 Mil as of Mar. 2026. GuruFocus rates WAR:PUR with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Pure Biologics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was zł-1.76 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was zł-6.58 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pure Biologics's annualized ROC % for the quarter that ended in Mar. 2026 was -40.73%. Pure Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11,111.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pure Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -14.88%.

Pure Biologics (WAR:PUR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pure Biologics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-6.784 * ( 1 - 0% )	/	( (16.488	+	16.822)	/ 2 )
=	-6.784	/	16.655
=	-40.73 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.94	-	2.594	-	( 0.01	-	max(0, 18.955	-	4.813	+	0.01	))
=	16.488

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.589	-	1.157	-	( 1.022	-	max(0, 17.979	-	1.589	+	1.022	))
=	16.822

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pure Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.056	/	( ( (0.127 + max(-2.703, 0))	+	(0 + max(-1.109, 0)) )	/	2 )
=	-7.056	/	( ( 0.127	+	0 )	/	2 )
=	-7.056	/	0.0635
=	-11,111.81 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.298	+	0	+	0.08)	-	(2.594	+	0	+	0.487)
=	-2.703

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.34	+	0	+	0.084)	-	(1.157	+	0	+	0.376)
=	-1.109

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pure Biologics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-6.578	/	44.199
	=	-14.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pure Biologics EBIT Related Terms

Pure Biologics EBIT Historical Data

* Premium members only.

The historical data trend for Pure Biologics's EBIT can be seen below:

Pure Biologics EBIT Chart

Pure Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-11.54

-25.27

-9.28

-11.86

-5.64

Pure Biologics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-0.80	-2.55	-0.90	-1.36	-1.76

WAR:PUR vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Pure Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pure Biologics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pure Biologics's EV-to-EBIT falls into.

Save Embed

20GF Score

Pure Biologics SA WAR:PUR

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pure Biologics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-6.58 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of zł-6.58 Mil mean?

Pure Biologics (WAR:PUR) has a EBIT of zł-6.58 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pure Biologics.

Is Pure Biologics' EBIT too high?

Pure Biologics' current EBIT is zł-6.58 Mil. Overall, Pure Biologics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does Pure Biologics' EBIT compare to VRTX and REGN?

Pure Biologics' EBIT of zł-6.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pure Biologics. Pure Biologics's current EBIT is zł-6.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pure Biologics stock overvalued right now?

Pure Biologics (WAR:PUR) has a current EBIT of zł-6.58 Mil. The current EBIT is zł-6.58 Mil. Pure Biologics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Pure Biologics (WAR:PUR), the current EBIT is zł-6.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pure Biologics Business Description

Industry Healthcare Biotechnology

Comparable Companies WAR:GX1 WAR:SCS WAR:PHR WAR:RDG WAR:URT WAR:NNG WAR:PTG VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM

Address ul. Dunska 11, Wroclaw, POL, 54-427

Website http://www.purebiologics.pl

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

20GF Score

Get the complete analysis for WAR:PUR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł2.35

Price

View WAR:PUR Analysis

See EBIT data for all stocks →